abstract_id,session_title,abstract_title,ground_truth,default_model_primary_drugs,default_model_secondary_drugs,default_model_comparator_drugs,default_model_reasoning,default_model_success,default_model_llm_calls
6022,,"A Prospective, Open-Label, Multicenter, Randomized Controlled Study Comparing the Efficacy and Safety of Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab (Pola-RCHP-X) Versus RCHOP-X and Pola-Rchp in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma",,"[""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone"", ""Orelabrutinib"", ""Chidamide"", ""Venetoclax"", ""Lenalidomide"", ""Penpulimab""]",[],"[""RCHOP-X"", ""Pola-RCHP""]","[""1. Normalized title and identified drug candidates and regimen abbreviations"", ""2. Detected 'Comparing' keyword indicating comparator structure per classification guidelines"", ""3. Identified Pola-RCHP-X as the primary treatment arm containing: Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone combined with Orelabrutinib/Chidamide/Venetoclax/Lenalidomide/Penpulimab"", ""4. Expanded all individual drug names from the combination regimen per inclusion rules"", ""5. Classified RCHOP-X and Pola-RCHP as Comparator drugs based on 'Versus' keyword"", ""6. Kept abbreviated regimens RCHOP-X and Pola-RCHP as comparators since they represent distinct treatment arms being compared against"", ""7. Applied formatting rules: maintained title casing, used ;; separator where needed"", ""8. Validated final JSON structure and ensured all drugs intended for treatment were captured""]",True,1
148,,Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classical Hodgkin Lymphoma Treated with BrECADD and eBEACOPP in the HD21 Trial,,"[""BrECADD"", ""eBEACOPP""]",[],[],"[""1. Normalized title and identified candidate drug-like terms: BrECADD, eBEACOPP, CIPN"", ""2. Excluded 'CIPN' as it refers to a condition (Chemotherapy-Induced Peripheral Neuropathy), not a drug"", ""3. Analyzed context: 'treated with' indicates therapeutic administration of BrECADD and eBEACOPP"", ""4. Identified 'and' as conjunction indicating co-primary drugs being studied in the HD21 trial"", ""5. BrECADD and eBEACOPP are abbreviated regimens; no expanded forms present in title, so captured as-is per inclusion rules"", ""6. Classified both BrECADD and eBEACOPP as Primary drugs"", ""7. Applied formatting rules and validated final JSON structure""]",True,1
671,,Novel Targeted Agents in Combination with R-MINE (RMINE+X) Based on Different Molecular Subtypes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma:a Phase 2 Multicenter Study,,"[""Rituximab"", ""Mesna"", ""Ifosfamide"", ""Mitoxantrone"", ""Etoposide""]",[],[],"[""1. Normalized title and identified candidate drug phrases: R-MINE, RMINE+X, Novel Targeted Agents"", ""2. Recognized R-MINE as an abbreviated regimen; expanded to component drugs: Rituximab, Mesna, Ifosfamide, Mitoxantrone, Etoposide"", ""3. Excluded 'Novel Targeted Agents' as it is a general drug class term, not a specific drug name per exclusion rules"", ""4. Excluded 'RMINE+X' as it represents a variable combination notation, not a specific drug"", ""5. 'in Combination with' indicates co-primary administration of the R-MINE components"", ""6. Classified all R-MINE component drugs as Primary"", ""7. Applied formatting rules: maintained title casing, used ;; separator between drugs"", ""8. Validated output as complete JSON with all required fields""]",True,1
4792,,"A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics",,"[""Glofitamab"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Vincristine"", ""Prednisolone"", ""Polatuzumab Vedotin""]",[],[],"[""1. Normalized title and identified drug-like phrases and regimen abbreviations"", ""2. Detected candidates: Glofitamab, R-CHOP, Polatuzumab Vedotin, R-CHP"", ""3. Expanded R-CHOP to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone per inclusion rules (capture individual drugs when regimen is present)"", ""4. Expanded R-CHP to Rituximab, Cyclophosphamide, Doxorubicin, Prednisolone (CHP variant without Vincristine)"", ""5. Identified 'or' keyword indicating both arms are Primary treatment options being studied"", ""6. Classified all drugs as Primary: Glofitamab appears in both arms, R-CHOP components and Polatuzumab Vedotin are co-administered therapies"", ""7. Removed duplicate Rituximab, Cyclophosphamide, Doxorubicin, Prednisolone entries"", ""8. Applied formatting rules and validated final JSON output""]",True,1
2723,,Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel,,"[""Idecabtagene Vicleucel"", ""Ciltacabtagene Autoleucel""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: Idecabtagene Vicleucel, Ciltacabtagene Autoleucel"", ""2. Both candidates are CAR-T cell therapies (specific products) used for treatment of multiple myeloma"", ""3. The phrase 'treated with' followed by 'or' indicates both drugs are primary therapeutic agents being studied"", ""4. 'or' identifier indicates both drugs are Primary (per guideline example 13: Drug A or Drug B \u2192 both Primary)"", ""5. No secondary or comparator identifiers present; no exclusion rules apply"", ""6. Applied formatting rules: maintained title casing, no abbreviations to expand"", ""7. Validated output as complete JSON with all required fields""]",True,1
2983,,The Effects of Tranexamic Acid and Recombinant Activated Factor VII on Traumatic Bleeding and Mortality in Mice,,"[""Tranexamic Acid"", ""Recombinant Activated Factor VII""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Tranexamic Acid, Recombinant Activated Factor VII"", ""2. Verified both candidates against inclusion rules - both are therapeutic agents used for treatment of bleeding"", ""3. Analyzed context: 'and' indicates co-administration/co-evaluation as primary therapeutic agents"", ""4. No secondary or comparator identifiers present (no 'with or without', 'versus', etc.)"", ""5. Classified both Tranexamic Acid and Recombinant Activated Factor VII as Primary drugs"", ""6. Applied formatting rules: maintained title casing, used ;; separator in array format"", ""7. Validated output as complete JSON with all required fields""]",True,1
3344,,Real World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma,,"[""Axicabtagene Ciloleucel"", ""Lisocabtagene Maraleucel""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Axicabtagene Ciloleucel, Lisocabtagene Maraleucel"", ""2. Both candidates are CAR-T cell therapies (specific products) used for treatment of relapsed/refractory DLBCL"", ""3. Analyzed context: 'Comparison of' indicates both drugs are being evaluated against each other in real-world setting"", ""4. Applied classification logic: 'Comparison of Drug A and Drug B' structure indicates both are primary treatments being compared, not a versus/comparator relationship"", ""5. Verified both drugs meet inclusion criteria as cell-based therapies for therapeutic use"", ""6. Classified both Axicabtagene Ciloleucel and Lisocabtagene Maraleucel as Primary Drugs"", ""7. Applied formatting rules: maintained title casing, used ;; separator in array format"", ""8. Validated final JSON structure and output""]",True,1
3677,,Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide,,"[""Belantamab Mafodotin"", ""Pomalidomide"", ""Dexamethasone""]",[],"[""Bortezomib""]","[""1. Normalized title and identified drug-like phrases: Belantamab Mafodotin, Pomalidomide, Dexamethasone, Bortezomib, Lenalidomide"", ""2. Analyzed structure: 'Plus' indicates co-primary drugs in first arm; 'Vs' indicates comparator arm"", ""3. First arm: Belantamab Mafodotin plus Pomalidomide and Dexamethasone \u2192 all three classified as Primary"", ""4. Second arm: Pomalidomide plus Bortezomib and Dexamethasone \u2192 Pomalidomide and Dexamethasone already in Primary; Bortezomib classified as Comparator due to 'Vs'"", ""5. Lenalidomide mentioned in context of prior therapy ('received 1 prior line of therapy including Lenalidomide'), not as current treatment \u2192 excluded per exclusion rule 4"", ""6. Applied formatting rules and validated JSON structure""]",True,1
564,,"Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) Results in Higher Remission Rates over Conventional 7+3 Chemotherapy without Increased Toxicity in Newly Diagnosed Acute Myeloid Leukemia",,"[""Venetoclax"", ""Cladribine"", ""Idarubicin"", ""Cytarabine""]",[],"[""7+3""]","[""1. Normalized title and identified candidate drug phrases: Venetoclax, Cladribine, Idarubicin, Cytarabine, CLIA, 7+3, conventional chemotherapy"", ""2. Excluded 'conventional chemotherapy' per exclusion rules (broad therapy term)"", ""3. Identified 'Combined with' as Primary drug identifier indicating co-administration"", ""4. CLIA is abbreviated regimen form of Cladribine, Idarubicin, Cytarabine; expanded form present so captured individual drugs only per inclusion rules"", ""5. Identified 'over' as comparator identifier; 7+3 is valid 2-3 letter drug regimen representing comparator arm"", ""6. Classified Venetoclax, Cladribine, Idarubicin, Cytarabine as Primary drugs"", ""7. Classified 7+3 as Comparator drug"", ""8. Applied formatting rules and validated final JSON output""]",True,1
876,,Tandem CAR-T-Cell Therapy Targeting CD5 and CD7: Facilitating Condition-Free Engraftment of Epitope-Edited Allogeneic HSCs,,"[""CD5-Targeted CAR-T Cell"", ""CD7-Targeted CAR-T Cell"", ""Allogeneic Hematopoietic Stem Cell""]",[],[],"[""1. Normalized title and identified therapeutic components: Tandem CAR-T-Cell Therapy Targeting CD5 and CD7, epitope-edited allogeneic HSCs"", ""2. Extracted candidates: CD5-targeted CAR-T, CD7-targeted CAR-T, allogeneic HSCs (hematopoietic stem cells)"", ""3. Applied CAR-T capture rules: CD5 and CD7 are specific targets, formatted as 'CD5-Targeted CAR-T Cell' and 'CD7-Targeted CAR-T Cell' per directed/targeted CAR-T formatting guidelines"", ""4. Applied stem cell normalization rules: 'allogeneic HSCs' expanded to 'Allogeneic Hematopoietic Stem Cell' per stem cell therapy mapping, removing 'transplantation' procedural term"", ""5. Identified 'Tandem' and 'Targeting' as indicating co-administration for treatment; all three components are Primary drugs used therapeutically"", ""6. No secondary or comparator indicators present; no exclusions apply"", ""7. Formatted output per formatting rules with proper capitalization and singular forms where applicable""]",True,1
4835,,"Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL",,"[""CD19-CAR T Cell"", ""CD22-CAR T Cell"", ""Allogeneic Hematopoietic Cell""]",[],[],"[""1. Normalized title and identified therapeutic components: CD19/CD22-CAR T cells and Allo-HCT (allogeneic hematopoietic cell transplantation)"", ""2. Extracted candidates: CD19-CAR T Cell, CD22-CAR T Cell, Allogeneic Hematopoietic Cell (from Allo-HCT)"", ""3. Applied cell therapy capture rules: CD19/CD22-CAR T cells captured as separate targeted CAR-T variants per formatting guidelines"", ""4. Applied stem cell normalization: 'Allo-HCT' (allogeneic hematopoietic cell transplantation) normalized to 'Allogeneic Hematopoietic Cell' per stem cell therapy rules"", ""5. 'Combination of' and 'with' indicate co-administration; all classified as Primary drugs"", ""6. No secondary or comparator drugs identified; applied formatting rules and validated JSON output""]",True,1
3429,,"ASC4REAL: Efficacy and Tolerability Comparison between Ascembl Study, a Phase 3 Randomized Clinical Trial (RCT), and Consolidated Real-World (RW) Evidence with Asciminib in CML Patients Beyond 2 TKIs",,"[""Asciminib""]",[],[],"[""1. Normalized title and identified candidate drug-like terms: Asciminib, TKIs"", ""2. Evaluated 'Asciminib' as a specific drug name used for treatment in CML patients"", ""3. Excluded 'TKIs' as it represents a broad drug class (tyrosine kinase inhibitors), not a specific drug, per exclusion rules"", ""4. No identifiers present indicating Secondary or Comparator classification; study compares trial vs real-world evidence of same drug"", ""5. Classified Asciminib as Primary drug being studied"", ""6. Applied formatting rules and validated final JSON output""]",True,1
3489,,Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up,,"[""Ibrutinib""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: Ibrutinib"", ""2. Verified Ibrutinib is a therapeutic drug used for treatment of CLL per inclusion rules"", ""3. Context indicates 'Treatment with First-Line Ibrutinib' - no identifiers suggesting secondary or comparator classification"", ""4. No other drugs mentioned in the title; no combination therapy indicators present"", ""5. Classified Ibrutinib as Primary drug as it is the main therapeutic agent being studied"", ""6. Applied formatting rules and validated final JSON structure""]",True,1
4343,,Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia,,"[""Revumenib""]",[],[],"[""1. Normalized title and identified candidate drug-like terms: Revumenib, KMT2Ar"", ""2. Analyzed context: 'Revumenib' is the therapeutic agent being studied in the AUGMENT-101 Phase 2 Study"", ""3. Excluded 'KMT2Ar' as it refers to a genetic rearrangement (KMT2A-rearranged), not a drug"", ""4. No identifiers for Secondary or Comparator drugs present in title"", ""5. Classified Revumenib as Primary drug (main therapeutic agent being evaluated)"", ""6. Applied formatting rules and validated output JSON structure""]",True,1
4356,,Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia,,"[""Enzomenib"", ""DSP-5336""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: Enzomenib, DSP-5336, Menin-MLL Inhibitor"", ""2. Recognized Enzomenib and DSP-5336 as brand name and code name for the same drug based on parenthetical notation"", ""3. Excluded 'Menin-MLL Inhibitor' as it represents mechanism of action per exclusion rules"", ""4. No identifiers present for Secondary or Comparator classification; single agent study context"", ""5. Classified both Enzomenib and DSP-5336 as Primary drugs (both names preserved per inclusion rules for brand/generic variants)"", ""6. Applied formatting rules and validated final JSON structure""]",True,1
4460,,Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study,,"[""Rituximab""]",[],[],"[""1. Normalized title and identified candidate phrases: Watchful Waiting, Rituximab"", ""2. Excluded 'Watchful Waiting' as it is a clinical observation strategy, not a drug or therapeutic agent"", ""3. Identified 'Rituximab' as a therapeutic drug for treatment"", ""4. Analyzed context: 'Vs.' indicates comparison, but 'Watchful Waiting' is not a drug, so no Comparator drug exists"", ""5. Classified Rituximab as Primary drug (main therapeutic agent being studied)"", ""6. Applied formatting rules and validated output JSON structure""]",True,1
4461,,"Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from ""FOLL12"" Phase III Trial of the Fondazione Italiana Linfomi",,"[""Rituximab""]",[],[],"[""1. Normalized title and identified candidate drug-like terms: Rituximab"", ""2. Analyzed context: 'Rituximab maintenance' indicates therapeutic use in follicular lymphoma treatment"", ""3. Verified Rituximab meets inclusion criteria as a therapeutic agent being studied"", ""4. No identifiers present for Secondary or Comparator classification; classified as Primary"", ""5. Excluded 'Minimal Residual Disease Analysis' as it is a diagnostic/monitoring term, not a therapeutic drug"", ""6. Applied formatting rules and validated final JSON output""]",True,1
4617,,"ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia",,"[""Mitapivat""]",[],"[""Placebo""]","[""1. Normalized title and identified candidate drug-like terms: Mitapivat, Placebo"", ""2. Analyzed study design keywords: 'Placebo-Controlled' indicates Placebo as comparator arm"", ""3. Identified Mitapivat as the investigational drug being studied (Primary)"", ""4. Classified Placebo as Comparator per 'versus' or 'compared to' equivalent context in controlled study design"", ""5. Applied formatting rules and validated final JSON structure""]",True,1
4724,,Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial,,"[""Lacutamab""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases"", ""2. Extracted candidate: Lacutamab"", ""3. Verified Lacutamab is a therapeutic agent (monoclonal antibody) used for treatment"", ""4. 'Treated By' indicates Lacutamab is the main therapeutic agent being studied"", ""5. No identifiers present for Secondary or Comparator classification"", ""6. Classified Lacutamab as Primary drug"", ""7. Applied formatting rules and validated output JSON""]",True,1
4751,,"Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO)",,"[""Divesiran""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: Divesiran, Galnac"", ""2. Analyzed 'Divesiran' as a novel siRNA therapeutic agent being evaluated in the study"", ""3. Identified 'Galnac' as a conjugation technology/delivery mechanism, not a standalone therapeutic drug"", ""4. Excluded 'Galnac' per exclusion rules as it represents a drug delivery mechanism rather than a therapeutic agent"", ""5. No identifiers present indicating Secondary or Comparator classification; Divesiran is the main therapeutic being studied"", ""6. Classified Divesiran as Primary drug"", ""7. Applied formatting rules and validated final JSON output""]",True,1
4866,,A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3,,"[""Ianalumab""]",[],[],"[""1. Normalized title and identified candidate drug-like terms: Ianalumab"", ""2. Verified Ianalumab is a therapeutic drug being studied in Phase 2 trial"", ""3. No identifiers present indicating secondary or comparator relationships"", ""4. 'Previously Treated with at Least Two Lines of Therapy' refers to prior treatment context, not current study drugs per exclusion rule 4"", ""5. Classified Ianalumab as Primary drug as it is the main therapeutic agent being evaluated"", ""6. Applied formatting rules and validated final JSON output""]",True,1
5173,,"HSP-CAR30, an Academic Memory-Enriched CART30, for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and CD30+ T Cell Lymphoma: Clinical Results of a Phase I/II Trial",,"[""HSP-CAR30""]",[],[],"[""1. Normalized title and identified candidate therapeutic terms: HSP-CAR30, Memory-Enriched CART30"", ""2. Recognized HSP-CAR30 as a specific CAR-T cell therapy variant being studied"", ""3. Determined 'Memory-Enriched CART30' is a descriptive term for the same therapy (HSP-CAR30), not a separate drug"", ""4. Applied cell therapy capture rules: HSP-CAR30 is a CAR-T variant with specific naming"", ""5. No identifiers for Secondary or Comparator drugs present in title"", ""6. Classified HSP-CAR30 as Primary drug (main therapeutic agent being studied)"", ""7. Formatted output per formatting rules and validated JSON structure""]",True,1
5613,,Iptacopan Monotherapy in Patients with Cold Agglutinin Disease: Phase II Study Results,,"[""Iptacopan""]",[],[],"[""1. Normalized title and identified candidate drug-like terms: Iptacopan, Monotherapy"", ""2. Excluded 'Monotherapy' as it is a treatment descriptor, not a drug name"", ""3. Identified 'Iptacopan' as the therapeutic agent being studied"", ""4. No identifiers present for Secondary or Comparator classification (no 'with or without', 'versus', etc.)"", ""5. Classified Iptacopan as Primary drug (single agent being evaluated in the study)"", ""6. Applied formatting rules and validated output JSON structure""]",True,1
66,,"Phase 1 Healthy Volunteer Study of DISC-3405, a Recombinant Humanized Antibody Targeting TMPRSS6",,"[""DISC-3405""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: DISC-3405, recombinant humanized antibody, TMPRSS6"", ""2. Recognized DISC-3405 as a drug name (alphanumeric identifier for therapeutic agent)"", ""3. Excluded 'recombinant humanized antibody' as it describes the drug mechanism/type, not a drug name per exclusion rules"", ""4. Excluded 'TMPRSS6' as it is a target/mechanism, not a therapeutic drug per exclusion rules"", ""5. No identifiers present indicating Secondary or Comparator classification; DISC-3405 is the main therapeutic agent being studied"", ""6. Classified DISC-3405 as Primary drug"", ""7. Applied formatting rules and validated final JSON output""]",True,1
3323,,"Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials",,"[""Cyclophosphamide"", ""Doxorubicin"", ""Vincristine"", ""Prednisolone"", ""Anti-CD20""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: Mini-CHOP, Anti-CD20"", ""2. Recognized Mini-CHOP as a drug regimen abbreviation for Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (CHOP components)"", ""3. Applied inclusion rule: captured individual drug names from Mini-CHOP regimen rather than the abbreviated form"", ""4. Identified Anti-CD20 as a therapeutic agent (monoclonal antibody class used for treatment)"", ""5. Analyzed 'Plus' keyword indicating co-administration; classified all drugs as Primary"", ""6. Excluded 'attenuated chemotherapy' as a broad therapy term per exclusion rules"", ""7. Applied formatting rules: maintained title casing, used ;; separator between drugs"", ""8. Validated output JSON structure and completeness""]",True,1
2640,,Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with R-GemOx: A Multi-Center Retrospective Cohort Study,,"[""R-GemOx""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases: R-GemOx"", ""2. R-GemOx is a recognized abbreviated regimen (Rituximab, Gemcitabine, Oxaliplatin)"", ""3. No expanded form of R-GemOx is present in the title, so the abbreviated regimen is captured per inclusion rules"", ""4. 'Treated with' indicates R-GemOx is the primary therapeutic intervention being studied"", ""5. No identifiers for Secondary or Comparator drugs detected"", ""6. Classified R-GemOx as Primary drug"", ""7. Applied formatting rules and validated output JSON""]",True,1
1356,,Split-Dose R-CHOP for Older Patients with Treatment Naive DLBCL,,"[""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Vincristine"", ""Prednisolone""]",[],[],"[""1. Normalized title and identified 'R-CHOP' as a drug regimen abbreviation"", ""2. R-CHOP is a well-known regimen consisting of: Rituximab, Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Vincristine (Oncovin), and Prednisolone/Prednisone"", ""3. Since only the abbreviated form 'R-CHOP' is present without expanded drug names, captured individual component drugs per inclusion rules for regimens"", ""4. No identifiers present indicating Secondary or Comparator classification; all drugs are part of the primary treatment regimen"", ""5. Classified all component drugs as Primary"", ""6. Applied formatting rules: singular form, proper casing, separated by semicolons""]",True,1
1208,,Real World Outcomes with Evolving Management of Cytokine Release Syndrome in CAR-T Therapy,,"[""CAR-T Cell""]",[],[],"[""1. Normalized title and identified candidate therapeutic terms: CAR-T Therapy"", ""2. Recognized 'CAR-T Therapy' as a cell-based therapeutic intervention"", ""3. Applied cell therapy capture rules: standardized to 'CAR-T Cell' per formatting guidelines"", ""4. Verified CAR-T Cell is used for treatment context (not diagnostic or eligibility)"", ""5. No identifiers present for Secondary or Comparator classification; classified as Primary"", ""6. Excluded 'Cytokine Release Syndrome' as it is a condition/adverse event, not a drug"", ""7. Formatted output per rules: singular form 'CAR-T Cell' with proper capitalization"", ""8. Validated final JSON structure and completeness""]",True,1
3863,,Preclinical Efficacy of Decoy-Resistant IL-18 in Hematological Malignancies,,"[""Decoy-Resistant IL-18""]",[],[],"[""1. Normalized title and identified candidate drug-like phrases"", ""2. Detected 'Decoy-Resistant IL-18' as a laboratory-produced compound being tested"", ""3. Verified IL-18 is a therapeutic agent (engineered interleukin variant) per inclusion rules for laboratory-produced compounds"", ""4. No identifiers present indicating secondary or comparator classification"", ""5. Classified Decoy-Resistant IL-18 as Primary drug"", ""6. Applied formatting rules and validated JSON structure""]",True,1
2663,,Reduced FDG Uptake in the Brain on Baseline 18FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Intravascular Large B-Cell Lymphoma and Advanced-Stage Diffuse Large B-Cell Lymphoma,,[],[],[],"[""1. Normalized title and identified potential drug-like terms: FDG, 18FDG"", ""2. Analyzed context: FDG/18FDG mentioned as diagnostic imaging agent (PET/CT scan), not as therapeutic treatment"", ""3. Applied exclusion rules: diagnostic agents used for detection/imaging purposes should be excluded unless used therapeutically"", ""4. Confirmed FDG is used for prognostic assessment (predicting prognosis), not for treatment of lymphoma"", ""5. No therapeutic drugs identified in title; all arrays remain empty"", ""6. Validated output as valid JSON with empty arrays per special instructions""]",True,1
686,,"The Effectiveness of Levofloxacin in Prevention of Febrile Episodes in Non-Hodgkin Lymphoma Patients Receiving Rituximab, Cyclophosphamide, Vincristine, Doxorubicin and Prednisolone (R-CHOP)",,"[""Levofloxacin""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Levofloxacin, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisolone, R-CHOP"", ""2. Analyzed context: Levofloxacin is used for prevention (therapeutic purpose); R-CHOP drugs are mentioned as background therapy in 'patients receiving' context"", ""3. Applied exclusion rule: drugs previously/currently used to treat patients should be excluded when mentioned in context of a new drug being studied"", ""4. R-CHOP components (Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisolone) are background therapy, not the focus of effectiveness study"", ""5. Excluded R-CHOP and its expanded components as they represent prior/concurrent treatment context, not the intervention being evaluated"", ""6. Classified Levofloxacin as Primary drug (main therapeutic agent being studied for prevention)"", ""7. Formatted output per formatting rules and validated JSON structure""]",True,1
661,,"Combination of Mitoxantrone Hydrochloride Liposome with Gemcitabine, Cisplatin and Dexamethasone in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: A Phase I Study",,"[""Mitoxantrone Hydrochloride Liposome"", ""Gemcitabine"", ""Cisplatin"", ""Dexamethasone""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Mitoxantrone Hydrochloride Liposome, Gemcitabine, Cisplatin, Dexamethasone"", ""2. Verified all candidates against inclusion rules - all are valid therapeutic drugs"", ""3. Analyzed identifier 'Combination of...with' indicating co-administration of multiple drugs"", ""4. Classified all four drugs as Primary based on combination therapy context"", ""5. No secondary or comparator identifiers detected in title"", ""6. Applied formatting rules and validated final JSON structure""]",True,1
2339,,"Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone Regimen with or without Rituximab (CMOP+-R) Shows High Efficacy As a First-Line Treatment for Non-Hodgkin's Lymphoma: A Phase II Clinical Trial with Matching-Adjusted Indirect Treatment Comparison (MAIC) Analysis",,"[""Cyclophosphamide"", ""Mitoxantrone Hydrochloride Liposome"", ""Vincristine"", ""Prednisone""]","[""Rituximab""]",[],"[""1. Normalized title and identified drug candidates: Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, Prednisone, Rituximab"", ""2. Analyzed regimen structure: CMOP represents the combination of the four drugs listed"", ""3. Identified key phrase 'with or without Rituximab' which matches Secondary Drug identifier per classification guidelines"", ""4. Classified Cyclophosphamide, Mitoxantrone Hydrochloride Liposome, Vincristine, and Prednisone as Primary Drugs (part of core regimen)"", ""5. Classified Rituximab as Secondary Drug due to 'with or without' conditional administration pattern"", ""6. No comparator drugs identified; no 'versus', 'compared to', or similar identifiers present"", ""7. Applied formatting rules: maintained title casing, used ;; separator format internally, verified singular forms"", ""8. Validated final JSON structure and ensured all arrays contain properly formatted drug names""]",True,1
335,,"Updated Results from a Phase II Study Hyper-CVAD, with or without Inotuzumab Ozogamicin, and Sequential Blinatumomab in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia",,"[""Hyper-CVAD"", ""Blinatumomab""]","[""Inotuzumab Ozogamicin""]",[],"[""1. Normalized title and identified candidate drug phrases: Hyper-CVAD, Inotuzumab Ozogamicin, Blinatumomab"", ""2. Analyzed identifier 'with or without' preceding Inotuzumab Ozogamicin, classifying it as Secondary per guidelines"", ""3. Identified 'sequential' indicating Blinatumomab is administered as part of primary treatment regimen"", ""4. Classified Hyper-CVAD as Primary (main regimen being studied)"", ""5. Classified Blinatumomab as Primary (sequential administration as part of main treatment)"", ""6. No comparator drugs identified; applied formatting rules and validated JSON structure""]",True,1
706,,"The Primary Results of R-MTO Regimen (Rituximab, Methotrexate, Thiotepa, and Orelabrutinib) As the First-Line Induction Therapy Followed By Autologous Stem Cell Transplantation in Newly Diagnosed Primary Central Nervous System Lymphoma",,"[""Rituximab"", ""Methotrexate"", ""Thiotepa"", ""Orelabrutinib"", ""Autologous Stem Cell""]",[],[],"[""1. Normalized title and identified candidate drug phrases: R-MTO regimen, Rituximab, Methotrexate, Thiotepa, Orelabrutinib, Autologous Stem Cell Transplantation"", ""2. Expanded R-MTO regimen to individual drugs per inclusion rules (prefer expanded form over abbreviation)"", ""3. Captured individual drugs: Rituximab, Methotrexate, Thiotepa, Orelabrutinib as Primary drugs"", ""4. Applied stem cell therapy normalization rule: 'Autologous Stem Cell Transplantation' \u2192 'Autologous Stem Cell' (removed procedural term 'Transplantation')"", ""5. All drugs are part of first-line induction therapy with no identifiers indicating Secondary or Comparator classification"", ""6. Classified all as Primary drugs; applied formatting rules and validated JSON output""]",True,1
2076,,"Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group",,"[""Isatuximab"", ""Bortezomib"", ""Cyclophosphamide"", ""Dexamethasone"", ""Lenalidomide""]",[],[],"[""1. Normalized title and identified drug-like phrases: Isatuximab, Bortezomib, Cyclophosphamide, Dexamethasone, Lenalidomide"", ""2. Analyzed context: 'in combination with' indicates co-primary drugs in induction phase"", ""3. Identified 'followed by' indicates sequential therapy with Isatuximab and Lenalidomide as maintenance"", ""4. All drugs are part of the treatment regimen with no secondary or comparator indicators present"", ""5. Classified all five drugs as Primary per inclusion rules"", ""6. Applied formatting rules and validated JSON structure""]",True,1
4684,,"Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study",,"[""Bortezomib"", ""Lenalidomide"", ""Dexamethasone""]","[""Daratumumab""]",[],"[""1. Normalized title and identified drug-like phrases: Bortezomib, Lenalidomide, Dexamethasone, Daratumumab"", ""2. Analyzed context: 'with or without Daratumumab' appears twice in the title, indicating optional addition to base regimen"", ""3. Applied classification rules: 'with or without' is a Secondary drug identifier per guidelines"", ""4. Classified Bortezomib, Lenalidomide, and Dexamethasone as Primary (base regimen drugs)"", ""5. Classified Daratumumab as Secondary (optional addition indicated by 'with or without')"", ""6. No comparator drugs identified (no 'versus', 'compared to', or similar identifiers present)"", ""7. Applied formatting rules: maintained title casing, used ;; separator where needed"", ""8. Validated output JSON structure and completeness""]",True,1
691,,"Updated Results from a Multicenter, Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma",,"[""Zanubrutinib"", ""Rituximab"", ""Methotrexate""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Zanubrutinib, Rituximab, Methotrexate"", ""2. Analyzed drug relationships using identifiers: 'in combination with' indicates co-primary administration"", ""3. Verified all three drugs are therapeutic agents intended for treatment of secondary CNS lymphoma"", ""4. 'Followed by Zanubrutinib maintenance' indicates continued use of Zanubrutinib as part of primary treatment regimen"", ""5. Classified Zanubrutinib, Rituximab, and Methotrexate as Primary drugs per inclusion rules"", ""6. Applied formatting rules: maintained title casing, used ;; separator, verified no exclusions apply"", ""7. Validated final JSON structure and output""]",True,1
337,,"Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update",,"[""Mini-Hypercvd"", ""Inotuzumab Ozogamicin""]","[""Blinatumomab""]",[],"[""1. Normalized title and identified candidate drug phrases: Mini-Hypercvd, Inotuzumab Ozogamicin (Ino), Blinatumomab (Blina)"", ""2. Expanded abbreviations: Ino \u2192 Inotuzumab Ozogamicin, Blina \u2192 Blinatumomab; captured full names per inclusion rules"", ""3. Analyzed identifier 'with/without' which indicates Secondary classification per guidelines"", ""4. Mini-Hypercvd and Inotuzumab Ozogamicin are co-administered (no 'with/without' applies to them) \u2192 classified as Primary"", ""5. Blinatumomab follows 'with/without' identifier \u2192 classified as Secondary"", ""6. Applied formatting rules: removed abbreviations in parentheses, maintained title casing, used ;; separator where needed""]",True,1
2505,,"A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome",,"[""Azacitidine"", ""Ipilimumab"", ""Nivolumab""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Azacitidine, Ipilimumab, Nivolumab"", ""2. Analyzed structure: 'Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab' indicates multiple treatment arms with co-administration"", ""3. Identified 'with' as primary co-administration indicator across all arms"", ""4. Analyzed 'with or without Azacitidine' phrase: this creates arms where Azacitidine may be optional, but it remains a primary treatment agent in the study design"", ""5. All three drugs (Azacitidine, Ipilimumab, Nivolumab) are being evaluated as therapeutic agents in various combinations"", ""6. No comparator drugs identified as no 'versus' or 'compared to' language present"", ""7. Applied formatting rules and validated output JSON""]",True,1
3338,,"Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma",,"[""Orelabrutinib"", ""Rituximab"", ""Thiotepa""]","[""High-Dose Methotrexate""]",[],"[""1. Normalized title and identified candidate drug phrases: Orelabrutinib, Rituximab, Thiotepa, High-Dose Methotrexate"", ""2. Removed dosage descriptor 'High-Dose' from Methotrexate per formatting rules, keeping drug name as Methotrexate"", ""3. Analyzed phrase structure: 'ORT in Combination with or without High-Dose Methotrexate'"", ""4. Identified 'with or without' as Secondary drug identifier per classification guidelines"", ""5. Classified Orelabrutinib, Rituximab, and Thiotepa as Primary (part of ORT regimen, main therapeutic agents)"", ""6. Classified Methotrexate as Secondary (indicated by 'with or without' phrase)"", ""7. No comparator drugs identified (no 'vs', 'versus', 'compared to' present)"", ""8. Applied formatting rules: removed dosage information, maintained title casing, used ;; separator"", ""9. Validated output JSON structure and completeness""]",True,1
3705,,Personalized Neoantigen Peptide Vaccine with or without Lenalidomide for Patients with Intermediate or High Risk Smoldering Multiple Myeloma (SMM) to Prevent Progression to Multiple Myeloma (MM),,"[""Personalized Neoantigen Peptide Vaccine""]","[""Lenalidomide""]",[],"[""1. Normalized title and identified candidate therapeutic phrases: Personalized Neoantigen Peptide Vaccine, Lenalidomide"", ""2. Analyzed context: 'with or without' is a key identifier indicating Secondary drug classification per guidelines"", ""3. Classified Personalized Neoantigen Peptide Vaccine as Primary (main therapeutic agent being studied)"", ""4. Classified Lenalidomide as Secondary (optional addition indicated by 'with or without')"", ""5. No comparator drugs identified (no 'vs', 'versus', 'compared to' present)"", ""6. Applied formatting rules: maintained title casing, used singular form where applicable"", ""7. Validated output as complete JSON with all required fields""]",True,1
4980,,"Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial",,"[""Acalabrutinib"", ""Venetoclax""]","[""Obinutuzumab""]","[""Chemoimmunotherapy""]","[""1. Normalized title and identified candidate drug phrases: Acalabrutinib, Venetoclax, Obinutuzumab, Chemoimmunotherapy"", ""2. Analyzed connectors: 'Plus' indicates co-primary administration between Acalabrutinib and Venetoclax"", ""3. Identified 'with or without' before Obinutuzumab, which per Secondary Drug guidelines indicates Obinutuzumab is Secondary"", ""4. Identified 'Versus' before Chemoimmunotherapy, indicating it is in the Comparator arm"", ""5. Evaluated Chemoimmunotherapy: recognized as a broad therapy class term, but kept as Comparator since it represents the control arm being compared against"", ""6. Applied formatting rules and validated final JSON structure""]",True,1
2232,,"Patient-Reported Outcomes in Older Acute Myeloid Leukemia Patients Fit for Intensive Treatment, Who Received Intensified Treatment (DA +/- cladribine) Following No Evidence of Response to Course 1: Results from the NCRI AML18 Trial",,"[""Daunorubicin"", ""Cytarabine""]","[""Cladribine""]",[],"[""1. Normalized title and identified candidate drug-like phrases: DA, cladribine"", ""2. Recognized 'DA' as a standard AML regimen abbreviation for Daunorubicin + Cytarabine"", ""3. Expanded 'DA' to individual drugs: Daunorubicin and Cytarabine per inclusion rules for 2-3 letter regimens with identifiable drugs"", ""4. Identified '+/-' symbol indicating 'with or without' relationship per Secondary Drug identifiers"", ""5. Classified Daunorubicin and Cytarabine as Primary Drugs (base regimen)"", ""6. Classified Cladribine as Secondary Drug due to '+/-' (with or without) indicator"", ""7. Applied formatting rules: maintained title casing, used ;; separator, singular forms"", ""8. Validated output as complete JSON with all required fields""]",True,1
1209,,Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone,,"[""Axicabtagene Ciloleucel""]","[""Dexamethasone""]",[],"[""1. Normalized title and identified candidate drug-like phrases: Axicabtagene Ciloleucel, Dexamethasone"", ""2. Analyzed context: 'treated with' indicates Axicabtagene Ciloleucel is the main therapeutic agent"", ""3. Identified 'with or without' as key identifier for Secondary classification per guidelines"", ""4. Classified Axicabtagene Ciloleucel as Primary (main treatment being studied)"", ""5. Classified Dexamethasone as Secondary (prophylactic use with 'with or without' identifier)"", ""6. Applied formatting rules: maintained proper casing and validated JSON structure""]",True,1
514,,Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab,,"[""Crovalimab""]",[],"[""Eculizumab""]","[""1. Normalized title and identified candidate drug phrases: Crovalimab, Eculizumab"", ""2. Analyzed context: 'switched from' indicates patients previously on Eculizumab are now receiving Crovalimab"", ""3. Crovalimab is the main therapeutic agent being studied for safety and efficacy (Primary)"", ""4. Eculizumab is the prior treatment being compared against in the switch context (Comparator)"", ""5. Applied formatting rules and validated output structure""]",True,1
987,,A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma,,"[""CD19-CAR-T Cell""]","[""Rituximab""]",[],"[""1. Normalized title and identified candidate drug-like phrases: CD19 CAR T-Cells, Rituximab, lymphodepletion"", ""2. Excluded 'lymphodepletion' as it is a procedural term, not a therapeutic drug"", ""3. Captured 'CD19 CAR T-Cells' following cell therapy capture rules as 'CD19-CAR-T Cell' with proper formatting"", ""4. Identified 'with or without Rituximab' as a Secondary drug identifier per classification guidelines"", ""5. Classified CD19-CAR-T Cell as Primary and Rituximab as Secondary based on identifier analysis"", ""6. Applied formatting rules: maintained capitalization, used singular form, proper hyphenation for CAR-T"", ""7. Validated output JSON structure and completeness""]",True,1
1743,,"Preliminary Data of a Single-Arm, Phase II Study of Orelabrutinib with/without Rituximab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma after BTK Inhibitor Therapy",,"[""Orelabrutinib""]","[""Rituximab""]",[],"[""1. Normalized title and identified candidate drug phrases: Orelabrutinib, Rituximab, BTK Inhibitor"", ""2. Analyzed context: 'with/without' is a secondary drug identifier per classification guidelines"", ""3. Excluded 'BTK Inhibitor' as it represents a mechanism of action/drug class per exclusion rules"", ""4. Classified Orelabrutinib as Primary drug (main therapeutic agent being studied)"", ""5. Classified Rituximab as Secondary drug due to 'with/without' identifier indicating optional combination"", ""6. Applied formatting rules and validated JSON structure""]",True,1
4283,,"Motixafortide (CXCR4 Inhibition) Alone and in Combination with Natalizumab (VLA-4 Inhibition) As a Novel Regimen to Mobilize Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease: A First-in-Human, Proof-of-Principle Safety and Feasibility Study",,"[""Motixafortide"", ""Natalizumab""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Motixafortide, CXCR4 Inhibition, Natalizumab, VLA-4 Inhibition"", ""2. Excluded 'CXCR4 Inhibition' and 'VLA-4 Inhibition' as mechanisms of action per exclusion rules"", ""3. Identified 'Alone and in Combination with' as key identifier indicating both drugs are Primary"", ""4. Classified Motixafortide and Natalizumab as Primary drugs based on co-administration pattern"", ""5. No Secondary or Comparator drugs identified in the title"", ""6. Applied formatting rules and validated final JSON output""]",True,1
3964,,Olutasidenib Alone or in Combination with Azacitidine in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data,,"[""Olutasidenib"", ""Azacitidine""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Olutasidenib, Azacitidine"", ""2. Analyzed context: 'Alone or in Combination with' indicates Olutasidenib as monotherapy and in combination with Azacitidine"", ""3. Applied classification guidelines: 'alone or in combination with' pattern matches Secondary drug identifier, but Azacitidine is part of the combination arm being studied"", ""4. Re-evaluated: Both drugs are being studied as therapeutic interventions (Olutasidenib monotherapy arm and Olutasidenib+Azacitidine combination arm)"", ""5. Classified both Olutasidenib and Azacitidine as Primary drugs since both are main therapeutic agents being evaluated in the study"", ""6. Applied formatting rules: maintained title casing, used ;; separator between drugs"", ""7. Validated output JSON structure and completeness""]",True,1
560,,"Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up",,"[""Gemtuzumab Ozogamicin"", ""Fludarabine"", ""Cytarabine"", ""G-CSF""]",[],"[""Idarubicin""]","[""1. Normalized title and identified drug-like phrases: Gemtuzumab Ozogamicin, Fludarabine, Cytarabine, G-CSF, FLAG-GO, Idarubicin, FLAG-IDA"", ""2. Expanded FLAG-GO regimen to individual drugs: Fludarabine, Cytarabine, G-CSF, Gemtuzumab Ozogamicin"", ""3. 'Added to' indicates co-administration; all drugs in FLAG-GO classified as Primary"", ""4. 'Than' indicates comparison; Idarubicin (from FLAG-IDA) classified as Comparator"", ""5. Excluded abbreviated regimen names (FLAG-GO, FLAG-IDA) as expanded forms are present"", ""6. Applied formatting rules and validated output JSON""]",True,1
6012,,"SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)",,"[""Glofitamab"", ""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone""]",[],"[""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone""]","[""1. Normalized title and identified drug candidates: Glofitamab, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, and abbreviated regimen Pola-R-CHP"", ""2. Expanded Pola-R-CHP abbreviation to its full drug components: Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone"", ""3. Identified 'Plus' and '+' as primary drug indicators showing co-administration in first arm: Glofitamab plus Pola-R-CHP components"", ""4. Identified 'Versus' as comparator indicator: second arm (Pola-R-CHP alone) serves as comparator"", ""5. Classified first arm drugs (Glofitamab + all Pola-R-CHP components) as Primary Drugs"", ""6. Classified second arm drugs (Pola-R-CHP components only) as Comparator Drugs"", ""7. Applied formatting rules: maintained title casing, used ;; separator, removed spaces"", ""8. Validated output JSON structure and completeness""]",True,1
569,,Comparison of FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax for Treatment of Newly Diagnosed AML in Patients Eligible for Intensive Induction. Analysis of 200 Consecutive Patients Treated at a Single Center,,"[""FLAG-Idarubicin""]","[""Venetoclax""]",[],"[""1. Normalized title and identified candidate drug phrases: FLAG-Idarubicin, Venetoclax"", ""2. Analyzed structure: 'FLAG-Idarubicin to FLAG-Idarubicin Plus Venetoclax' indicates comparison of two treatment arms"", ""3. Identified 'Plus' as key identifier indicating Venetoclax is added optionally to FLAG-Idarubicin in one arm"", ""4. Applied classification rules: FLAG-Idarubicin appears in both arms (Primary); Venetoclax added with 'Plus' in optional combination context (Secondary)"", ""5. Verified FLAG-Idarubicin is a valid regimen containing Fludarabine, Cytarabine, G-CSF, and Idarubicin; captured as regimen per inclusion rules"", ""6. Formatted output per formatting rules and validated JSON structure""]",True,1
6089,,"Guidance 05: A Prospective, Multicenter, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Genotype-Guided Targeted Agents in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (POLA-RCHP-X) Versus Pola-Rchp in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma",,"[""Polatuzumab Vedotin"", ""Rituximab"", ""Cyclophosphamide"", ""Doxorubicin"", ""Prednisone""]",[],[],"[""1. Normalized title and identified drug candidates: Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone, POLA-RCHP-X, Pola-Rchp"", ""2. Recognized POLA-RCHP-X and Pola-Rchp as abbreviated regimens with expanded forms present in parentheses"", ""3. Applied inclusion rule: when both expanded and abbreviated forms present, capture only expanded drug names"", ""4. Excluded 'Genotype-Guided Targeted Agents' as it is a broad therapy class term, not a specific drug"", ""5. Identified 'in Combination with' and 'and' as Primary drug identifiers indicating co-administration"", ""6. Identified 'Versus' but both arms contain the same base drugs; the comparator arm (Pola-Rchp) is the abbreviated form already captured in expanded form"", ""7. Classified all five expanded drugs as Primary; no Secondary or Comparator drugs identified"", ""8. Applied formatting rules: maintained title casing, used ;; separator (not needed here as array format), verified singular forms""]",True,1
1305,,Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma,,"[""EPOCH"", ""DCEP""]",[],[],"[""1. Normalized title and identified candidate drug-like terms: EPOCH, DCEP"", ""2. Recognized both EPOCH and DCEP as abbreviated drug regimens (2-5 letters)"", ""3. Verified no expanded forms present in title; captured abbreviated regimens per inclusion rules"", ""4. Identified 'Comparison of' structure indicating both regimens are being compared as treatment options"", ""5. Determined both EPOCH and DCEP are Primary drugs as they are the main therapeutic regimens being studied/compared for treatment"", ""6. No secondary or comparator drugs identified based on context and identifiers"", ""7. Applied formatting rules and validated final JSON output""]",True,1
1216,,"Comparison of Tacrolimus/Methotrexate and Post-Transplant Cyclophosphamide Graft-Versus Host Disease Prophylaxis for Haploidentical and Matched Allogeneic Stem Cell Transplantation Demonstrates Improved Overall Survival and Reduced Mortality, Shorter Length of Stay, Less Peritransplant Toxicity with Post-Transplant Cyclophosphamide",,"[""Tacrolimus"", ""Methotrexate"", ""Cyclophosphamide""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Tacrolimus, Methotrexate, Cyclophosphamide, Allogeneic Stem Cell"", ""2. Excluded 'Allogeneic Stem Cell' as it refers to stem cell transplantation procedure context (prophylaxis comparison), not treatment administration"", ""3. Identified 'Comparison of' keyword indicating comparative study structure"", ""4. Analyzed drug relationships: Tacrolimus/Methotrexate (combination regimen) and Post-Transplant Cyclophosphamide (separate regimen) are being compared as two prophylaxis approaches"", ""5. Both regimens are primary therapeutic interventions being evaluated; 'comparison' here describes study design rather than establishing a comparator arm with 'versus' or 'compared to'"", ""6. Classified all three drugs as Primary since both prophylaxis regimens represent active therapeutic approaches being studied"", ""7. Applied formatting rules: maintained title casing, used ;; separator between drugs"", ""8. Validated final JSON structure and output""]",True,1
1217,,Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine for Allogeneic Hematopoietic Cell Transplantation in Patients with Lymphomas in the Ptcy Era: A Study on Behalf of the Grupo Espanol De Trasplante y Terapia Celular (GETH-TC),,"[""Treosulfan"", ""Fludarabine"", ""Thiotepa"", ""Busulfan""]",[],[],"[""1. Normalized title and identified drug-like phrases: Treosulfan, Fludarabine, Thiotepa, Busulfan, Allogeneic Hematopoietic Cell Transplantation"", ""2. Analyzed structure: 'Treosulfan/Fludarabine Versus Thiotepa/Busulfan/Fludarabine' indicates two regimen arms being compared"", ""3. Identified 'Versus' as comparator identifier, but both arms contain therapeutic drugs being studied"", ""4. Applied context analysis: both regimens are conditioning therapies for transplantation, making all drugs primary therapeutic agents in their respective arms"", ""5. Excluded 'Allogeneic Hematopoietic Cell Transplantation' as it is a procedural term, not a drug"", ""6. Classified Treosulfan, Fludarabine, Thiotepa, and Busulfan as Primary drugs since both regimens are being evaluated as treatment options"", ""7. Applied formatting rules: maintained title casing, used ;; separator between drugs""]",True,1
3780,,High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI),,"[""Isatuximab"", ""Lenalidomide"", ""Dexamethasone"", ""Bortezomib""]",[],[],"[""1. Normalized title and identified candidate drug phrases: Isatuximab, Lenalidomide, Dexamethasone, Bortezomib, Isard"", ""2. Analyzed 'Isard' as abbreviation for Isatuximab+Rd (Lenalidomide+Dexamethasone); expanded form present, so excluded abbreviation per rule 3"", ""3. Identified 'Plus' and 'with' as Primary drug indicators showing co-administration"", ""4. 'Versus' typically indicates comparator, but right side is 'Isard' which is the same drugs already captured; no new comparator drugs identified"", ""5. Classified Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib as Primary drugs"", ""6. Applied formatting rules and validated final JSON output""]",True,1
2691,,"Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study",,"[""Isatuximab"", ""Bortezomib"", ""Lenalidomide"", ""Dexamethasone""]",[],"[""Bortezomib"", ""Lenalidomide"", ""Dexamethasone""]","[""1. Normalized title and identified drug candidates: Isatuximab, Bortezomib, Lenalidomide, Dexamethasone, and the regimen abbreviations Isa-VRd and VRd"", ""2. Expanded regimen abbreviations: Isa-VRd = Isatuximab + Bortezomib + Lenalidomide + Dexamethasone; VRd = Bortezomib + Lenalidomide + Dexamethasone"", ""3. Identified 'Vs.' (versus) as the comparator indicator separating two treatment arms"", ""4. Classified Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone as Primary drugs (combination arm with Isatuximab)"", ""5. Classified Bortezomib, Lenalidomide, and Dexamethasone as Comparator drugs (VRd alone arm being compared against)"", ""6. Applied formatting rules and validated final JSON structure""]",True,1
4934,,"Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial",,"[""Belantamab Mafodotin"", ""Bortezomib"", ""Dexamethasone""]",[],"[""Daratumumab""]","[""1. Normalized title and identified drug-like phrases: Belantamab Mafodotin, Bortezomib, Dexamethasone, Daratumumab"", ""2. Analyzed structural pattern: 'Drug A, Drug B, and Drug C Vs Drug D, Drug E, and Drug F' indicates two treatment arms"", ""3. Identified 'Vs' (versus) as comparator indicator per classification guidelines"", ""4. First arm (Belantamab Mafodotin, Bortezomib, Dexamethasone) connected by commas and 'and' indicates co-primary administration"", ""5. Second arm (Daratumumab, Bortezomib, Dexamethasone) is the comparator arm; Bortezomib and Dexamethasone already captured in primary arm"", ""6. Classified Belantamab Mafodotin, Bortezomib, and Dexamethasone as Primary Drugs"", ""7. Classified Daratumumab as Comparator Drug (unique to comparator arm)"", ""8. Applied formatting rules: maintained title casing, used ;; separator, verified no duplicates"", ""9. Validated output JSON structure and completeness""]",True,1
659,,Comparison of Efficacy and Safety of Gdpt and CHOP in First-Line Treatment of Peripheral T-Cell Lymphoma,,"[""Gdpt""]",[],"[""CHOP""]","[""1. Normalized title and identified candidate drug-like phrases: Gdpt, CHOP"", ""2. Analyzed context: 'Comparison of' indicates comparative study structure"", ""3. Identified 'and' connecting Gdpt and CHOP, but overall structure shows comparison between two regimens"", ""4. Applied identifier 'Comparison' which maps to comparator classification per guidelines"", ""5. Classified Gdpt as Primary (first-mentioned regimen being studied) and CHOP as Comparator (standard regimen being compared against)"", ""6. Both are abbreviated regimens; kept as-is since expanded forms not present in title"", ""7. Applied formatting rules and validated JSON structure""]",True,1
2074,,"Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial",,"[""Belantamab Mafodotin"", ""Bortezomib"", ""Dexamethasone""]",[],"[""Daratumumab"", ""Bortezomib"", ""Dexamethasone""]","[""1. Normalized title and identified drug-like phrases: Belantamab Mafodotin, Bortezomib, Dexamethasone, Daratumumab"", ""2. Analyzed structure: 'treated with [drugs] plus [drugs] and [drugs] Vs [drugs]' indicates primary arm versus comparator arm"", ""3. Identified 'plus' and 'and' as co-primary indicators for first regimen: Belantamab Mafodotin, Bortezomib, Dexamethasone"", ""4. Identified 'Vs' as comparator indicator for second regimen: Daratumumab, Bortezomib, Dexamethasone"", ""5. Classified Belantamab Mafodotin + Bortezomib + Dexamethasone as Primary Drugs"", ""6. Classified Daratumumab + Bortezomib + Dexamethasone as Comparator Drugs (note: Bortezomib and Dexamethasone appear in both arms)"", ""7. Applied formatting rules and validated JSON structure""]",True,1
4668,,PET-Directed Therapy with ABVD Vs. Bv+AVD Followed By Nivolumab in Patients with Early Stage Hodgkin Lymphoma: A Propensity Score Matched Analysis of CALGB50604 and ACCRULY1601,,"[""ABVD"", ""Brentuximab Vedotin"", ""AVD"", ""Nivolumab""]",[],[],"[""1. Normalized title and identified candidate drug phrases: ABVD, Bv+AVD, Nivolumab"", ""2. Recognized 'Bv' as abbreviation for Brentuximab Vedotin based on standard oncology nomenclature"", ""3. Analyzed 'Vs.' (versus) as comparator indicator between two treatment arms"", ""4. First arm: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine regimen) - captured as abbreviated regimen since expanded form not present"", ""5. Second arm: Bv+AVD (Brentuximab Vedotin + doxorubicin, vinblastine, dacarbazine) - expanded Bv to full name, captured AVD as regimen"", ""6. 'Followed By' indicates sequential administration of Nivolumab in the second arm, classified as Primary"", ""7. Both treatment arms are being compared in study design; all drugs are therapeutic agents being evaluated, thus all classified as Primary"", ""8. Applied formatting rules: maintained capitalization, used ;; separator between drugs"", ""9. Validated final JSON structure and output""]",True,1
4822,,Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma,,"[""Carfilzomib"", ""Lenalidomide"", ""Dexamethasone""]",[],[],"[""1. Normalized title and identified drug-like phrases: Carfilzomib-Lenalidomide-Dexamethasone, Lenalidomide-Dexamethasone"", ""2. Extracted candidate drugs: Carfilzomib, Lenalidomide, Dexamethasone"", ""3. Analyzed identifier 'Vs' (versus) which typically indicates comparator relationship"", ""4. Observed that Lenalidomide and Dexamethasone appear in both arms of the comparison"", ""5. Determined that all three drugs (Carfilzomib, Lenalidomide, Dexamethasone) are being evaluated as therapeutic agents in different combinations"", ""6. Classified all three drugs as Primary since they are all main therapeutic agents being studied in the trial arms"", ""7. Applied formatting rules: maintained title casing, no dosage information present"", ""8. Validated output JSON structure and confirmed all drugs are intended for treatment of high-risk smoldering multiple myeloma""]",True,1
1041,,"Comparative Efficacy of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Aged 70 and Above: A Multicenter Study",,"[""Daratumumab"", ""Pomalidomide"", ""Dexamethasone""]",[],"[""Carfilzomib""]","[""1. Normalized title and identified drug-like phrases: Daratumumab, Pomalidomide, Dexamethasone, Carfilzomib"", ""2. Analyzed structure: 'Daratumumab, Pomalidomide and Dexamethasone' forms first regimen; 'Daratumumab, Carfilzomib and Dexamethasone' forms second regimen"", ""3. Identified 'Compared to' as comparator identifier indicating the second regimen is the comparator arm"", ""4. First regimen (Daratumumab, Pomalidomide, Dexamethasone) classified as Primary drugs using 'and' as co-administration indicator"", ""5. Second regimen contains Daratumumab (already in Primary) and Dexamethasone (already in Primary), so only Carfilzomib is new and classified as Comparator"", ""6. Applied formatting rules: maintained title casing, used ;; separator, verified all drugs are valid therapeutic agents"", ""7. Validated final JSON structure and ensured all arrays contain properly formatted strings""]",True,1
6067,,A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209,,"[""Bortezomib"", ""Lenalidomide"", ""Dexamethasone"", ""Daratumumab""]",[],[],"[""1. Normalized title and identified drug-like phrases: Bortezomib, Lenalidomide, Dexamethasone, Daratumumab"", ""2. Analyzed structure: 'comparing' indicates comparison between two regimens (VRd-Lite vs DRd)"", ""3. VRd-Lite regimen contains: Bortezomib (V), Lenalidomide (R), Dexamethasone (d)"", ""4. DRd regimen contains: Daratumumab (D), Lenalidomide (R), Dexamethasone (d)"", ""5. Both regimens are being compared as treatment arms; 'comparing' with 'with' indicates both are primary treatment options being evaluated"", ""6. Maintenance therapy mentions Lenalidomide and Daratumumab but these are already captured in primary regimens"", ""7. All four drugs classified as Primary since both arms represent active treatment comparisons in the trial design"", ""8. Applied formatting rules and validated output JSON""]",True,1
1758,,Comparisons between Haploidentical Hematopoietic Stem Cell Transplantation and Eltrombopag Adding to Standard Immunosuppression in Patients with Severe Aplastic Anemia,,"[""Eltrombopag""]",[],"[""Haploidentical Hematopoietic Stem Cell""]","[""1. Normalized title and identified candidate therapeutic terms: Haploidentical Hematopoietic Stem Cell Transplantation, Eltrombopag, Standard Immunosuppression"", ""2. Applied stem cell therapy normalization rules: 'Haploidentical Hematopoietic Stem Cell Transplantation' \u2192 'Haploidentical Hematopoietic Stem Cell' (removed 'Transplantation')"", ""3. Excluded 'Standard Immunosuppression' as it is a broad therapy class term per exclusion rules"", ""4. Identified 'Comparisons between' and 'and' structure indicating two treatment arms being compared"", ""5. Classified Eltrombopag as Primary (main therapeutic agent being studied with standard immunosuppression)"", ""6. Classified Haploidentical Hematopoietic Stem Cell as Comparator (being compared against Eltrombopag treatment)"", ""7. Applied formatting rules and validated JSON structure""]",True,1
6094,,"Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody",,"[""Talquetamab"", ""Pomalidomide"", ""Teclistamab""]",[],"[""Elotuzumab"", ""Dexamethasone"", ""Bortezomib""]","[""1. Normalized title and identified drug-like phrases and regimen combinations"", ""2. Extracted candidates: Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone, Bortezomib, Lenalidomide, Anti-CD38 Monoclonal Antibody"", ""3. Identified '+' as co-primary indicator in 'Talquetamab + Pomalidomide' and 'Talquetamab + Teclistamab'"", ""4. Identified 'Vs' as comparator indicator separating experimental arms from control arms (EPd and PVd regimens)"", ""5. Classified Talquetamab, Pomalidomide, and Teclistamab as Primary drugs (experimental arms)"", ""6. Classified Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib as Comparator drugs (from EPd and PVd regimens)"", ""7. Excluded Lenalidomide and Anti-CD38 Monoclonal Antibody as they appear in context of prior therapy eligibility criteria, not current treatment"", ""8. Excluded 'Anti-CD38 Monoclonal Antibody' as it is a drug class term, not a specific drug name"", ""9. Applied formatting rules and validated final JSON structure""]",True,1
4065,,"Comparison of Ixazomib, Lenalidomide Plus Dexamethasone (IRd) and Bortezomib, Lenalidomide Plus Dexamethasone (VRd) in Newly Diagnosed Multiple Myeloma in China",,"[""Ixazomib"", ""Lenalidomide"", ""Dexamethasone"", ""Bortezomib""]",[],[],"[""1. Normalized title and identified drug-like phrases: Ixazomib, Lenalidomide, Dexamethasone, Bortezomib, IRd, VRd"", ""2. Detected 'Comparison of' keyword indicating comparative study structure"", ""3. Analyzed regimen structure: IRd (Ixazomib, Lenalidomide, Dexamethasone) and VRd (Bortezomib, Lenalidomide, Dexamethasone)"", ""4. Applied inclusion rule: expanded regimen abbreviations are present, so captured individual drug names and excluded abbreviated forms (IRd, VRd)"", ""5. Identified 'Plus' as co-primary indicator in both regimens; 'and' between regimens indicates comparison of two primary treatment arms"", ""6. Classified all four drugs as Primary since both regimens are being compared as treatment options (no clear comparator arm designated)"", ""7. Applied formatting rules: maintained title casing, removed duplicates, ordered drugs logically"", ""8. Validated output JSON structure and completeness""]",True,1
3754,,"Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study",,"[""Selinexor"", ""Bortezomib"", ""Dexamethasone""]",[],"[""Bortezomib"", ""Dexamethasone""]","[""1. Normalized title and identified drug candidates: Selinexor, Bortezomib, Dexamethasone, and regimen abbreviations SVd and Vd"", ""2. Analyzed structure: 'SVd Versus Vd' indicates two treatment arms being compared"", ""3. First arm (SVd): Selinexor, Bortizomib, and Dexamethasone combined with 'and' - classified as Primary drugs per co-administration rules"", ""4. Second arm (Vd): Bortizomib and Dexamethasone - 'Versus' keyword indicates Comparator arm"", ""5. Note: Bortezomib and Dexamethasone appear in both arms (Primary in SVd, Comparator in Vd regimen)"", ""6. Applied formatting rules and validated JSON structure""]",True,1
4151,,Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study,,"[""Glofitamab"", ""Gemcitabine"", ""Oxaliplatin""]",[],"[""Rituximab"", ""Gemcitabine"", ""Oxaliplatin""]","[""1. Normalized title and identified drug-like phrases: Glofitamab, Gemcitabine, Oxaliplatin, Rituximab, Glofit-GemOx, R-GemOx"", ""2. Recognized Glofit-GemOx as abbreviated regimen containing Glofitamab + Gemcitabine + Oxaliplatin (expanded form present)"", ""3. Recognized R-GemOx as abbreviated regimen containing Rituximab + Gemcitabine + Oxaliplatin (expanded form present)"", ""4. Identified 'plus' keyword indicating co-primary administration for first arm: Glofitamab, Gemcitabine, Oxaliplatin"", ""5. Identified 'versus' keyword indicating comparator arm: Rituximab plus Gemcitabine and Oxaliplatin"", ""6. Classified Glofitamab, Gemcitabine, Oxaliplatin as Primary Drugs (first treatment arm)"", ""7. Classified Rituximab, Gemcitabine, Oxaliplatin as Comparator Drugs (comparison arm)"", ""8. Applied formatting rules and validated JSON structure""]",True,1
3971,,Glofitamab with Gemcitabine and Oxaliplatin Is Cost-Effective Versus Rituximab with Gemcitabine and Oxaliplatin for US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Were Not Candidates for Autologous Stem Cell Transplant,,"[""Glofitamab"", ""Gemcitabine"", ""Oxaliplatin""]",[],"[""Rituximab""]","[""1. Normalized title and identified drug-like phrases: Glofitamab, Gemcitabine, Oxaliplatin, Rituximab, Autologous Stem Cell Transplant"", ""2. Excluded 'Autologous Stem Cell Transplant' as it appears in context of patient eligibility (not candidates for), not as treatment being administered"", ""3. Identified 'with' connecting Glofitamab with Gemcitabine and Oxaliplatin, indicating co-primary administration"", ""4. Identified 'Versus' indicating Rituximab (with same backbone) as Comparator arm"", ""5. Classified Glofitamab, Gemcitabine, Oxaliplatin as Primary Drugs"", ""6. Classified Rituximab as Comparator Drug"", ""7. Applied formatting rules and validated final JSON output""]",True,1
5996,,"Trial in Progress: A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy",,"[""Venetoclax"", ""Azacitidine"", ""Cusatuzumab""]",[],[],"[""1. Normalized title and identified drug-like phrases: Venetoclax, Azacitidine, Cusatuzumab"", ""2. Analyzed structure: 'Venetoclax and Azacitidine Plus Cusatuzumab' versus 'Venetoclax and Azacitidine Alone'"", ""3. Identified 'Plus' as Primary drug identifier indicating co-administration of all three drugs in experimental arm"", ""4. Identified 'versus' with 'Alone' indicating comparator arm uses subset of same drugs (Venetoclax and Azacitidine)"", ""5. Since comparator arm uses same drugs as experimental arm (just without Cusatuzumab), all three drugs are Primary - no separate Comparator classification needed"", ""6. Applied formatting rules: maintained title casing, no dosage information present"", ""7. Validated all drugs are therapeutic agents intended for AML treatment per inclusion rules"", ""8. Generated final JSON with all three drugs classified as Primary""]",True,1
4796,,"Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial",,"[""Decitabine"", ""All-Trans Retinoic Acid""]",[],"[""Decitabine""]","[""1. Normalized title and identified candidate drug phrases: Decitabine, All-Trans Retinoic Acid, Decitabine Monotherapy"", ""2. Analyzed structure: 'Decitabine Plus All-Trans Retinoic Acid' indicates combination therapy with 'Plus' as identifier"", ""3. Identified 'versus' as comparator identifier separating two treatment arms"", ""4. Classified Decitabine and All-Trans Retinoic Acid as Primary drugs (combination arm per 'Plus' identifier)"", ""5. Classified Decitabine in monotherapy arm as Comparator drug (per 'versus' identifier)"", ""6. Applied formatting rules: maintained title casing, used ;; separator where needed, validated JSON structure""]",True,1
4960,,A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL),,"[""Mosunetuzumab"", ""Polatuzumab Vedotin""]",[],"[""Rituximab""]","[""1. Normalized title and identified candidate drug phrases: Mosunetuzumab SC, Polatuzumab Vedotin, Rituximab"", ""2. Removed route of administration 'SC' from Mosunetuzumab per exclusion rules"", ""3. Identified 'plus' keyword indicating co-primary administration for Mosunetuzumab and Polatuzumab Vedotin"", ""4. Identified 'versus' keyword indicating Rituximab plus Polatuzumab Vedotin as comparator arm"", ""5. Classified Mosunetuzumab and Polatuzumab Vedotin as Primary drugs (main treatment arm)"", ""6. Classified Rituximab as Comparator drug (comparison arm)"", ""7. Applied formatting rules: maintained title casing, used ;; separator, trimmed spaces"", ""8. Validated final JSON structure and output""]",True,1
549,,"Comparing the Efficacy and Safety of VAC (Venetoclax, Azacitidine, Chidamide) and VA Regimens As Induction Therapy for Newly Diagnosed Patients with Immunophenotypically Mature Monocytic AML",,"[""Venetoclax"", ""Azacitidine"", ""Chidamide""]",[],"[""Venetoclax"", ""Azacitidine""]","[""1. Normalized title and identified drug candidates: VAC regimen (Venetoclax, Azacitidine, Chidamide) and VA regimen"", ""2. Expanded VAC abbreviation to full drug names: Venetoclax, Azacitidine, Chidamide"", ""3. Expanded VA abbreviation to full drug names: Venetoclax, Azacitidine"", ""4. Identified 'Comparing' keyword indicating comparator relationship between VAC and VA regimens"", ""5. Classified VAC regimen drugs (Venetoclax, Azacitidine, Chidamide) as Primary based on 'and' connector within regimen"", ""6. Classified VA regimen drugs (Venetoclax, Azacitidine) as Comparator based on 'Comparing' keyword"", ""7. Applied formatting rules: removed spaces, used proper casing, separated multiple drugs with ;;"", ""8. Validated output JSON structure and completeness""]",True,1
2954,,"Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)",,"[""Recombinant Human Thrombopoietin"", ""rhTPO""]",[],"[""Eltrombopag""]","[""1. Normalized title and identified candidate drug phrases: Recombinant Human Thrombopoietin, rhTPO, Eltrombopag"", ""2. Recognized rhTPO as abbreviation for Recombinant Human Thrombopoietin; both forms present so captured both per inclusion rules"", ""3. Identified 'Versus' as comparator identifier indicating Eltrombopag is in comparator arm"", ""4. Classified Recombinant Human Thrombopoietin and rhTPO as Primary Drugs (main therapeutic agents being studied)"", ""5. Classified Eltrombopag as Comparator Drug (drug being compared against)"", ""6. Applied formatting rules: maintained title casing, used ;; separator between synonyms, validated JSON structure""]",True,1
2422,,Lymphodepletion with Fludarabine/Cyclophosphamide Shows Higher Complete Response Rates Compared to Bendamustine Prior to CAR-T Therapy,,"[""Fludarabine"", ""Cyclophosphamide"", ""CAR-T Cell""]",[],"[""Bendamustine""]","[""1. Normalized title and identified candidate drug phrases: Fludarabine, Cyclophosphamide, Bendamustine, CAR-T Therapy"", ""2. Converted 'CAR-T Therapy' to 'CAR-T Cell' per cell therapy capture rules"", ""3. Analyzed structure: 'Fludarabine/Cyclophosphamide' indicates fixed combination using '/' separator"", ""4. Identified 'Compared to' as comparator identifier, classifying Bendamustine as Comparator"", ""5. Classified Fludarabine, Cyclophosphamide, and CAR-T Cell as Primary drugs (lymphodepletion regimen administered with CAR-T therapy)"", ""6. Applied formatting rules: separated Fludarabine and Cyclophosphamide with ';;', maintained proper casing"", ""7. Validated final JSON structure and ensured all fields are populated correctly""]",True,1
2125,,Comparison of Rabbit ATLG and ATG in Allogeneic Hematopoietic Stem Cell Transplantation for Children with Acquired Severe Aplastic Anemia,,"[""Rabbit ATLG"", ""ATG"", ""Allogeneic Hematopoietic Stem Cell""]",[],[],"[""1. Normalized title and identified candidate phrases: Rabbit ATLG, ATG, Allogeneic Hematopoietic Stem Cell Transplantation"", ""2. Applied stem cell therapy normalization rules: 'Allogeneic Hematopoietic Stem Cell Transplantation' \u2192 'Allogeneic Hematopoietic Stem Cell'"", ""3. Identified 'Comparison of' keyword indicating both Rabbit ATLG and ATG are being compared as treatments"", ""4. Both Rabbit ATLG and ATG are therapeutic agents used in the transplantation context, classified as Primary drugs"", ""5. Allogeneic Hematopoietic Stem Cell is the transplant therapy being used for treatment, classified as Primary"", ""6. No secondary or comparator drugs identified based on keyword analysis"", ""7. Applied formatting rules and validated final JSON output""]",True,1
4404,,A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial,,"[""Cytarabine"", ""Venetoclax""]","[""Midostaurin""]",[],"[""1. Normalized title and identified candidate drug phrases: Cytarabine, Venetoclax, Midostaurin"", ""2. Analyzed drug relationship indicators: 'and' between Cytarabine and Venetoclax indicates co-primary administration"", ""3. Identified '+/-' symbol before Midostaurin, which per guidelines indicates Secondary classification (with or without pattern)"", ""4. No comparator indicators (vs, versus, compared to) detected; no Comparator drugs present"", ""5. Classified Cytarabine and Venetoclax as Primary Drugs, Midostaurin as Secondary Drug"", ""6. Applied formatting rules: maintained title casing, used ;; separator format, validated JSON structure""]",True,1
3641,,Bortezomib-melphalan-prednisone (VMP) +/- daratumumab (DVMP) vs. lenalidomide-dexamethasone (Rd) +/- daratumumab (DRd) in transplant-ineligible real-life multiple myeloma patients: Results from the randomized phase IV real MM trial,,"[""Bortezomib"", ""Melphalan"", ""Prednisone"", ""Lenalidomide"", ""Dexamethasone""]","[""Daratumumab""]",[],"[""1. Normalized title and identified drug-like phrases: Bortezomib, Melphalan, Prednisone, Daratumumab, Lenalidomide, Dexamethasone"", ""2. Analyzed VMP regimen: expanded to Bortezomib-Melphalan-Prednisone per inclusion rules for regimens"", ""3. Analyzed Rd regimen: expanded to Lenalidomide-Dexamethasone per inclusion rules"", ""4. Identified '+/-' symbol indicating optional addition of Daratumumab in both arms (DVMP and DRd)"", ""5. Per Secondary Drug guidelines, '+/-' (plus/minus symbol) indicates Daratumumab is Secondary in both treatment arms"", ""6. 'vs.' indicates comparison between two treatment arms, but both arms contain the same Secondary drug (Daratumumab), so no Comparator classification needed"", ""7. Classified Bortezomib, Melphalan, Prednisone, Lenalidomide, Dexamethasone as Primary drugs"", ""8. Classified Daratumumab as Secondary drug due to '+/-' identifier"", ""9. Applied formatting rules and validated JSON structure""]",True,1
185,,Beyond Classical Hodgkin Lymphoma: Long-Term Risks and Secondary Cancers-Insights from the Texas Cancer Registry,,[],[],[],"[""1. Normalized title and identified potential drug-like phrases"", ""2. Analyzed title content: focuses on 'Long-Term Risks and Secondary Cancers' from registry data"", ""3. No specific drug names, regimens, or therapeutic agents mentioned in the title"", ""4. Title describes an epidemiological/registry study examining outcomes, not drug interventions"", ""5. No candidates meet inclusion criteria for drug extraction"", ""6. Output empty arrays for all drug categories per special instructions""]",True,1
289,,Data Driven Research through the European RADeep Registry and the Use of Artificial Intelligence Towards Personalized Medicine in Sickle Cell Disease,,[],[],[],"[""1. Normalized title and identified potential drug-like terms"", ""2. Analyzed title content: focuses on data-driven research, registry, artificial intelligence, and personalized medicine"", ""3. No specific drug names, regimens, or therapeutic agents identified in the title"", ""4. Terms present are methodological (registry, artificial intelligence) and disease-related (Sickle Cell Disease) but not therapeutic drugs"", ""5. Applied exclusion rules: no drugs intended for treatment are mentioned"", ""6. Concluded no drugs meet inclusion criteria; returned empty arrays for all categories""]",True,1
319,,CSF3RT618I Is Stabilized By Calnexin and Induces Unfolded Protein Response (UPR) and ER-Phagy: A Pro-Survival Pathway for Oncogenic Misfolded CSF3R Proteins in Chronic Neutrophilic Leukemia (CNL),,[],[],[],"[""1. Normalized title and identified candidate terms: CSF3RT618I, Calnexin, UPR, ER-Phagy, CSF3R"", ""2. Analyzed each candidate against inclusion/exclusion rules"", ""3. CSF3RT618I and CSF3R are proteins/receptors, not therapeutic drugs - excluded per exclusion rules"", ""4. Calnexin is an endogenous protein chaperone, not administered therapeutically - excluded per body compounds exclusion"", ""5. UPR (Unfolded Protein Response) and ER-Phagy are biological mechanisms/pathways, not drugs - excluded per mechanisms exclusion"", ""6. No therapeutic drugs, vaccines, cell therapies, or drug regimens identified in title"", ""7. Title describes biological mechanisms in disease context, not drug treatment"", ""8. Returned empty arrays for all categories as no drugs meet inclusion criteria""]",True,1
340,,Results of the ALL-IC REL 2016 Registry Trial: 1st Relapses of Childhood ALL Treated in High-Middle Income Countries,,[],[],[],"[""1. Normalized title and identified potential drug-like terms"", ""2. Detected 'ALL-IC REL 2016' as registry trial identifier, not a drug"", ""3. No specific drug names, regimens, or therapeutic agents mentioned in title"", ""4. Title describes a registry trial for childhood ALL relapses but does not specify treatment drugs"", ""5. Applied exclusion rules: no drugs identified for extraction"", ""6. Output empty arrays for all categories per special instructions""]",True,1
408,,Real World Data on the Utility of P-Selectin Expression Assay; Correlation of Test Results and Disease Expression,,[],[],[],"[""1. Normalized title and identified candidate phrases: 'P-Selectin Expression Assay'"", ""2. Analyzed context: title focuses on diagnostic/prognostic utility of an assay, not therapeutic intervention"", ""3. P-Selectin Expression Assay is a diagnostic test/assay, not a therapeutic drug per exclusion rules"", ""4. No therapeutic drugs, drug regimens, or cell therapies identified in title"", ""5. Applied exclusion rules for assays and tests; no drugs meet inclusion criteria"", ""6. Output empty arrays for all drug categories""]",True,1
450,,"TP53, CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial",,[],[],[],"[""1. Normalized title and identified potential drug-like terms"", ""2. Analyzed title content: focuses on molecular markers (TP53, CD36 mutations, CDKN2A loss) as predictors of outcome"", ""3. Identified 'V-Rbac' as potential drug regimen candidate"", ""4. Evaluated V-Rbac: appears to be a trial identifier/regimen name in context of 'FIL V-Rbac Phase 2 Trial'"", ""5. No clear therapeutic drugs mentioned for treatment administration"", ""6. Title focuses on prognostic/predictive molecular analysis rather than drug intervention"", ""7. No drugs meeting inclusion criteria identified; returned empty arrays per special instructions""]",True,1
503,,Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study,,[],[],[],"[""1. Normalized title and identified potential drug-like phrases"", ""2. Detected 'Second Line Therapy' as the only treatment-related term"", ""3. Applied exclusion rules: 'Second Line Therapy' is a broad therapy class term, not a specific drug"", ""4. No specific drug names, regimens, or therapeutic agents identified in the title"", ""5. Title describes a study context (Real World Evidence, Spanish Multicenter Study) rather than specific treatments"", ""6. Concluded no drugs meet inclusion criteria; returned empty arrays for all categories""]",True,1
620,,Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry,,[],[],[],"[""1. Normalized title and identified candidate phrases: 'Bruton Tyrosine Kinase Inhibitor', 'Chemotherapy'"", ""2. Analyzed 'Bruton Tyrosine Kinase Inhibitor' - this is a mechanism of action/drug class term, not a specific drug name"", ""3. Analyzed 'Chemotherapy' - this is a broad therapy class term per exclusion rules"", ""4. Applied exclusion rules: mechanisms of action and broad therapy terms must be excluded"", ""5. No specific drug names identified in the title that meet inclusion criteria"", ""6. Returned empty arrays for all categories as no therapeutic drugs were explicitly named""]",True,1
641,,"Real World Treatment Outcomes in the First Line Management of Waldenstrom Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical",,[],[],[],"[""1. Normalized title and identified potential drug-like phrases"", ""2. Analyzed title content: 'Real World Treatment Outcomes in the First Line Management of Waldenstrom Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical'"", ""3. No specific drug names, regimens, or therapeutic agents identified in the title"", ""4. Title describes a registry study analyzing treatment outcomes but does not specify which drugs were used"", ""5. 'Whimsical' appears to be the registry name, not a drug"", ""6. Applied exclusion rules: no therapeutic agents present to extract"", ""7. Returned empty arrays for all drug categories as no drugs were identified""]",True,1
801,,Adolescents and Young Adults (AYA) with Myeloproliferative Neoplasms (MPNs): Analysis of Patient Outcomes and Impact of High-Molecular Risk Mutations,,[],[],[],"[""1. Normalized title and identified potential drug-like terms"", ""2. Analyzed title content: focuses on patient outcomes analysis and molecular risk mutations in MPNs"", ""3. No therapeutic drugs, regimens, or treatments mentioned in the title"", ""4. Terms present are disease names (Myeloproliferative Neoplasms), patient population (Adolescents and Young Adults), and study focus (outcomes, mutations)"", ""5. No drugs identified per inclusion/exclusion rules; returning empty arrays for all categories""]",True,1
919,,Gene Therapy for Artemis-SCID and Artemis-Leaky-SCID Patients: Preliminary Results of the French Artegene Phase I/II Clinical Trial,,[],[],[],"[""1. Normalized title and identified candidate therapeutic terms: 'Gene Therapy'"", ""2. Analyzed 'Gene Therapy' - this is a broad therapeutic modality/class term, not a specific drug or regimen"", ""3. Applied exclusion rules: broad therapy-class terms (chemotherapy, radiotherapy, immunotherapy, gene therapy) must be excluded"", ""4. No specific drug names, cell therapies, vaccines, or other includable therapeutic agents identified in the title"", ""5. Verified no drugs meet inclusion criteria; returned empty arrays for all categories"", ""6. Formatted output as valid JSON with empty arrays""]",True,1
968,,Age Is a Crucial Determinant of GFRS with Incidence of Severe Chronic GVHD Reducing over Time in Haemopoietic Cell Transplantation for Transfusion Dependent Thalassaemia: Real World Data from 2010-2021. an Analysis of the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Working Party,,[],[],[],"[""1. Normalized title and identified potential drug-like terms"", ""2. Detected 'Haemopoietic Cell Transplantation' as a procedural term, not a therapeutic drug"", ""3. No specific drug names, regimens, or therapeutic agents identified in the title"", ""4. Title focuses on clinical outcomes (GFRS, GVHD) and patient characteristics (age) rather than drug interventions"", ""5. Applied exclusion rules: no drugs intended for treatment are mentioned"", ""6. Output empty arrays for all categories as no drugs were identified""]",True,1
1023,,Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry,,[],[],[],"[""1. Normalized title and identified potential drug-like terms"", ""2. Analyzed title content: focuses on chromosomal abnormalities, risk definition, and registry reporting"", ""3. No therapeutic agents, drug names, regimens, or cell therapies mentioned"", ""4. Title describes a classification/registry study rather than a therapeutic intervention"", ""5. No drugs identified for extraction; returning empty arrays for all categories""]",True,1
1043,,Real World Efficacies of First Line Treatments in Non-Transplant-Eligible Newly Diagnosed (ND-NTE) Multiple Myeloma (MM) Patients: A Challenge to Maia ? an Analysis from the Austrian Myeloma Registry (AMR),,[],[],[],"[""1. Normalized title and identified potential drug-like terms"", ""2. Detected 'MAIA' which refers to a clinical trial name, not a drug"", ""3. No specific drug names, regimens, or therapeutic agents mentioned in the title"", ""4. Title focuses on treatment efficacy analysis and registry data rather than specific drugs"", ""5. Applied exclusion rules: no drugs identified for extraction"", ""6. Output empty arrays for all categories per special instructions""]",True,1
1061,,Health Resource Utilization Among Patients with Warm Autoimmune Hemolytic Anemia in Sweden: A Retrospective Registry-Based Study,,[],[],[],"[""1. Normalized title and identified potential drug-related terms"", ""2. Analyzed title content: 'Health Resource Utilization Among Patients with Warm Autoimmune Hemolytic Anemia in Sweden: A Retrospective Registry-Based Study'"", ""3. No drug names, regimens, cell therapies, vaccines, or therapeutic agents identified in the title"", ""4. Title describes a retrospective registry-based study focused on health resource utilization, not drug administration or treatment"", ""5. No therapeutic interventions mentioned; study is observational/epidemiological in nature"", ""6. Applied exclusion rules: no drugs to extract"", ""7. Returned empty arrays for all drug categories per special instructions""]",True,1
1098,,Complementary and Alternative Medicine (CAM) Use Reported Among Individuals with Immune Thrombocytopenia (ITP): Data from the ITP Natural History Study Registry,,[],[],[],"[""1. Normalized title and identified potential drug-related terms"", ""2. Detected 'Complementary and Alternative Medicine (CAM)' as a broad therapy class term"", ""3. Applied exclusion rules: CAM is a general therapy category, not a specific drug or regimen"", ""4. No specific drug names, cell therapies, vaccines, or therapeutic agents identified in the title"", ""5. Title focuses on data collection/registry study rather than drug administration for treatment"", ""6. Concluded no drugs meet inclusion criteria; returned empty arrays for all categories""]",True,1
1123,,Chive-Impact: Establishing the Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE) Registry and Biorepository in Underserved Areas,,[],[],[],"[""1. Normalized title and identified potential drug-like terms"", ""2. Analyzed title content: 'Chive-Impact', 'Clonal Hematopoiesis', 'Inflammation', 'Vasculature', 'CHIVE', 'Registry', 'Biorepository', 'Underserved Areas'"", ""3. Determined that title describes establishment of a registry and biorepository for research purposes"", ""4. No therapeutic drugs, drug regimens, cell therapies, or vaccines mentioned in the title"", ""5. All terms relate to study infrastructure (registry/biorepository) or biological conditions (clonal hematopoiesis, inflammation) rather than treatments"", ""6. Applied exclusion rules: no drugs intended for treatment identified"", ""7. Output empty arrays for all drug categories per special instructions""]",True,1
1171,,Incorporating Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) into Dose Review in a Phase I Clinical Trial,,[],[],[],"[""1. Normalized title and tokenized for drug-like phrases"", ""2. Identified candidates: PRO-CTCAE (Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events)"", ""3. PRO-CTCAE is an assessment tool/framework, not a therapeutic drug or treatment"", ""4. No drug names, regimens, cell therapies, vaccines, or therapeutic compounds detected"", ""5. Title focuses on methodology for adverse event reporting in Phase I trials, not drug administration"", ""6. Applied exclusion rules: no therapeutic agents identified"", ""7. Output empty arrays for all categories per special instructions""]",True,1
1290,,Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis,,[],[],[],"[""1. Normalized title and identified potential drug-like phrases"", ""2. No specific drug names detected in the title"", ""3. Title focuses on treatment patterns and outcomes analysis rather than specific therapeutic agents"", ""4. No drug regimens, cell therapies, vaccines, or other includable therapeutic agents mentioned"", ""5. This is an observational registry analysis without specified drugs"", ""6. All drug arrays remain empty per special instructions for titles without identifiable drugs""]",True,1
